Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst

Merck's PD-1 superstar Keytruda has been growing exponentially thanks mainly to its lead in newly diagnosed non-small cell lung cancer. However, recent successes for immuno-oncology competitors could put some pressure on its near-term growth, one analyst says. But worry not, SVB Leerink analyst Daina Graybosch says: The drug still has other indications to lean on.